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Abstract: The roles of phenolics from olive oils as effective anticancer agents have been documented in
various in vitro studies of different cancer cells lines, but the relationship between the phenolic profile
of olive oil and its biological activity needs more elucidation. In this study, we analysed phenolic
profiles of extra virgin olive oils (EVOOs) from different autochthonous cultivars from Croatia (Oblica,
Bjelica, Buža, Žižolera) and investigated the biological effect of EVOO phenolic extracts (EVOO-PEs)
on human cervical (HeLa) and human colon (SW48) cancer cell lines alone and in combination
with cisplatin (cDDP), carboplatin (CBP), 5-fluorouracil (5-FU) and irinotecan. The quantitative
evaluation of olive oil polyphenols was performed by HPLC-DAD and spectrophotometric analysis.
The biological effect of EVOO-PEs alone and in combination with anticancer drugs was measured
by MTT assay. Analysed EVOO-PEs differ in phenolic profile and inhibited HeLa and SW48 cells
in a dose-dependent manner. Further, it is shown that EVOO-PEs (Oblica-Sea, Buža and Žižolera),
in combination with anticancer drugs, increase the metabolic activity of HeLa and SW48 cells and
have a protective role. These data imply careful consummation of olive oil during chemotherapy of
cancer patients.
Keywords: olive oil; phenolics; biological activity; cancer cells; anticancer drugs
1. Introduction
Cancer is one of the leading causes of deaths in the world. In 2018 there were 9.6 million cases of
deaths caused by cancer. According to the incident rate, lung, breast and colorectal cancer are three types
of cancer ranked within the top five in terms of mortality [1,2]. As the number of cancer cases and deaths
is constantly rising, cancer therapy presents one of the major medical challenges with the continuous need
for improvement in the therapeutic approach. The most effective approach in the treatment of cancer
is surgery combined with chemo and radiotherapy. Unfortunately, due to development of intrinsic or
acquired drug resistance as well as side effects of cancer treatment, there is a growing need for more
efficient anticancer agents and new strategies that could improve the success of cancer treatment. One of
the possibilities is combinations of existing anticancer drugs with polyphenols.
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Biological activity of single phenols, particularly hydroxytyrosol (HTyr), tyrosol (Tyr) and their
derivatives oleuropein (Ole), oleacein and oleocanthal (Oc) were largely investigated on different types
of cancer cells: colorectal, prostate, hepatocellular, pancreatic, cholangiocarcinoma, thyroid cancer,
glioma, neuroblastoma, lung cancer, promyelocytic leukaemia, melanoma, multiple myeloma and
non-melanoma skin cancer [3,4]. Anticancer properties seem to correlate with antioxidant activity of
phenolic compound present in olive oil [5]. In addition, indirect antioxidant potential protects normal
cells from oxidative damage [6]. These biological studies showed the beneficial effects of the most
abundant phenolics in olive oil. The subject of biological activity research is also the phenolic extract
of olive oil. Fabiani et al. [7] were studying the effects of olive oil phenolic extract in promyelocytic
leukaemia cells (HL60) and they noticed that polyphenols protect deoxyribonucleic acid (DNA) from
oxidative damage. The result of an in vitro study on colorectal cancer cell lines indicated that olive oil
phenolic extract showed inhibition of certain crucial stages in the development of colorectal cancer,
from initiation to promotion and metastasis [8]. Using the mouse model of colorectal cancer in the study,
olive oil phenolic extract showed a significant decrease of tumour size and metastasis [9]. Another
study of colon cancer cells in rats fed with EVOO analysed the effects of EVOO and its polyphenols on
gene expression of endocannabinoid system components via epigenetic regulation [10]. The results of
the study by Pampaloni et al. [11] indicate that EVOO-PE inhibited cell proliferation in colon cancer
cells with activation of receptors, acting similar to 17β-estradiol. The anti-metastatic effect caused
by polyphenols from EVOO was registered in human transitional bladder cancer cell line T24 [12].
Promising results were obtained in the study of topical application of EVOO-PE in the prevention
and treatment of non-melanoma skin cancers [13]. The results of the study by De Stefanis et al. [14]
indicate that EVOO extract enriched in ligstroside aglycone and oleocanthal have anti-proliferative
effects on human liver cancer cell lines. Oliveras-Ferraros et al. [15] concluded that crude phenolic
extracts from EVOO circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by
inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3. The results
of studying the effect of virgin olive oil phenolic extract on HeLa cells suggest that phenolic extract has
a protective effect against nuclear DNA damage in HeLa cells [16].
Moreover, the potential benefit of polyphenols in combination with different anticancer drugs was
investigated showing the synergistic, additive and antagonistic effect of polyphenols [17,18]. A great
number of investigations showed that single olive oil phenolics (Ole, Oc, HTyr, Ole aglycone) can
reduce toxic effects or modulate the activity of anticancer drugs such as alkylating agents: cDDP,
cyclophosphamide, dacarbazine (DTIC); plant alkaloids: paclitaxel; doxorubicin (DOX); monoclonal
antibodies: trastuzumab (Tzb), cetuximab; hormonal agents: tamoxifen; enzyme inhibitors: lapatinib,
vemurafenib; antineoplastic and immunomodulating agents: everolimus in different preclinical cancer
models [4]. To the best of our knowledge, there has been only one study of olive oil phenolic extract in
combination with anticancer drugs showing reduction of mitomycin C and paclitaxel anti-proliferative
effect in T24 and 5637 bladder cancer cells by EVOO-PE [19].
The aim of the present study was to investigate the phenolic content of EVOO-PEs isolated from
olive oils and their impact on tumour cell metabolic activity. In addition, we were interested in the
biological effect of EVOO-PEs in combination with broadly used anticancer drug irinotecan, 5-FU,
cDDP and CBP. Our goal was to obtain data which will additionally illuminate the use of olive oil in
the diet of cancer patients during chemotherapy.
2. Materials and Methods
2.1. Reagents and Standards
Glacial acetic acid, sodium molybdate dihydrate, sodium nitrite and aluminium chloride were
bought from Merck (Darmstadt, Germany). Methanol (HPLC grade), dimethyl sulfoxide (DMSO),
catechin and 2,2-Diphenyl-1-Picrylhydrazyl (DPPH), benzoic acid, hydroxytyrosol, p-coumaric acid,
homovanillyl alcohol, oleuropein, apigenin and pinoresinol were obtained from Sigma-Aldrich Chemie
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GmbH (Steinheim, Germany). Gallic acid, tyrosol, 3,4-dihydroxybenzoic acid, p-hydroxybenzoic acid,
vanillic acid, syringic acid, ferulic acid, cinnamic acid, o-coumaric acid and Folin-Ciocalteu’s reagent
were purchased from Fluka Chemie GmbH (Buchs, Switzerland), while vanillin and formic acid
(99+%) were obtained from Acros Organics (Morris Plains, NJ, USA). Sodium carbonate anhydrous
and sodium hydroxide were from Kemika (Zagreb, Croatia). Irinotecan was bought from Pfizer, USA,
while cisplatin (cDDP) and carboplatin (CBP) were obtained from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Olive Oil Samples
Fresh and healthy olive fruits of the variety Oblica (the island of Ugljan, Kali, Croatia) were
carefully selected upon the harvest. A portion of the fruit (50.0 kg) was immediately treated with the
Oliomio 350 centrifugal line to make EVOO Oblica. Another part of the olive fruit (50.0 kg) was stored
in seawater before processing on the same line to get olive oil (EVOO-Sea) [20]. Another three samples
were collected in Istrian Peninsula, Croatia: EVOO from variety Bjelica produced by Oleum Maris
d.o.o. (Vodnjan, Croatia) and EVOO from variety Buža and Žižolera produced by family farm OPG
Matteo Beluci (Vodnjan, Croatia). The samples were stored at 4 ◦C and kept out of light.
2.3. Extraction of Phenolic Compounds
The process of extraction of phenolic components from EVOO was carried out, with the
use of ultrasonic-assisted liquid-liquid extraction technique (US-LLE), previously described by
Jerman et al. [21] with some modification. EVOO sample (20.00 g) was dissolved in 10 mL of
n-hexane then methanol (15 mL) was added and sonicated (3 × 10 min at 25 ◦C) using an ultrasonic
bath (Elma Transsonic T570 HF = 320 W, Germany). Hettich centrifuge D-78532 (Tuttlingen, Germany)
was used to spin the homogenates from each of the three extraction phases (15 min at 4000 rpm).
Centrifuged homogenates were combined and shaken with n-hexane to degrease. The methanolic
EVOO extracts, divided into two equal portions, were concentrated at 38 ◦C using a Büchi Heating
Bath B-490 rotary evaporator (Büchi Labortechnik AG, Flawil, Switzerland). Two dried phenolic
extracts were obtained from each EVOO sample upon successive evaporation of the methanol. One
dried phenolic extract was re-dissolved in methanol for HPLC-DAD and spectrophotometric analysis
and the other one was dissolved in 2 mL of DMSO (100% stock solution) for biological activity test
(i.e., for the prepared solution of EVOO-PE with a dilution of 1% (v/v) 1 mL of the 100% stock solution
was diluted in 100 mL flask with DMSO).
2.4. HPLC-DAD Analysis
Following the procedure, according to Jakobušić Brala et al. [22] and Owen et al. [23], an HPLC-DAD
analysis was performed. HPLC analyses were performed in a Perkin Elmer Series 200 system (USA)
with diode array detector (DAD) at 25 ◦C. The column used in the analysis was C18 Restek column
(5 µm, 250 × 4.0 mm). The volume of the sample injected was 25 µL and the mobile phase contained
acetic acid (98:2, v/v) (A) and methanol (B). The flow rate was 1 mL/min, the total duration was 45 min.
The elution changes were: 95% A–5% B for 2 min, 75% A–25% B for 8 min; 60% A–40% B for 10 min, 50%
A–50% B for 10 min, and 0% A–100% B until the end of the run. The UV absorption of eluates at 278 nm
was monitored. Retention times (Rt) of phenolic compounds were compared with those of the standards.
The retention times (Rt) of the standards in this system were (min): gallic acid, 9.66; hydroxytyrosol,
12.02; 3,4-dihydroxybenzoic acid, 13.74; tyrosol, 15.66; p-hydroxybenzoic acid, 17.68; homovanillyl
alcohol, 18.13; vanillic acid, 20.18; syringic acid; 21.77, vanillin; 22.64, p-coumaric acid, 25.43; benzoic
acid; 26.50; ferulic acid, 27.02; o-coumaric acid, 28.81; oleuropein, 30.20 and cinnamic acid; 35.31;
pinoresinol 33.41, apigenin; 42.65. The retention time of oleacein (dialdehydic form of decarboxymethyl
elenolic acid linked to hydroxytyrosol, 3,4-DHPEA-EDA) was detected according to the literature [24].
Phenolic compounds were quantified by integrating the peaks and using the appropriate 6-point
calibration curves with authentic standards for all components except oleacein. Oleacein concentration
was calculated from the calibration curve for oleuropein by including differences in their molecular
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weights. Standards stock solutions (0.1 M) were prepared in HPLC methanol. Calibration concentrations
of standards were prepared in the range as expected for each compound in EVOO-PEs 0.3–80 µg/mL
(3,4-dihydroxybenzoic acid, p-hydroxybenzoic acid, homovanillyl alcohol, vanillic acid, syringic acid;
vanillin; p-coumaric acid, benzoic acid, ferulic acid, o-coumaric acid and cinnamic acid), 7–770 µg/mL
(hydroxytyrosol and tyrosol) and 135–2700 µg/mL (oleuropein), 8–135 µg/mL (apigenin), 10-180 µg/mL
(pinoresinol). Polytetrafluoroethylen (PTF) filters (0.20 µm/13 mm) from Macherey-Nagel GmbH & Co.
KG (Düren, Germany) were used to filter EVOO-PE and standard solutions were filter sterilised prior
to HPLC analysis using polytetrafluoroethylen (PTF) filters (0.20 µm/13 mm) (Macherey-Nagel GmbH
& Co. KG, Düren, Germany). Concentration values of phenolic compounds were expressed as mg of
phenol/kg of EVOO.
2.5. Total Phenols Analyses (TP)
The concentration of total phenols (TP) in methanolic EVOO-PEs was determined spectrophotometrically
with Folin-Ciocalteu (FC) reagent at 725 nm according to Gutfinger [25]. The EVOO-PEs aliquots,
5 mL water and 0.25 mL FC reagent were transferred to 10 mL volumetric flasks. 1.5 mL of saturated
(20%) sodium carbonate solution was added after 3 min to the reaction mixture. The solution was
then diluted to 10 mL with water. The absorbance was measured at 725 nm against a methanol
blank on UV-VIS spectrophotometer Hewlett Packard 8453 (Germany) two times after 30 min. Gallic
acid served as a standard for preparing the calibration curve ranging 170–1020 µg/mL assay solution
(y = 0.000833x + 0.0219; R2 = 0.9990; x: concentration of gallic acid in µg/mL; y: absorbance at 725 nm).
The concentration of TP in extracts was expressed as mg gallic acid equivalent (GAE)/kg of EVOO.
2.6. o-Diphenols Analyses
According to Mateos et al. [26] the o-diphenol concentration in methanolic EVOO-PE was
determined using sodium molybdate. Extract dilutions were prepared by mixing 0.5 mL of the extract
with methanol:water (1:1, v/v). 0.5 mL of a 5% sodium molybdate solution in methanol/water (1:1, v/v)
was added to 2 mL of diluted extract. The mixed content was in the dark for 15 min and the absorbance
was measured spectrophotometrically at 350 nm relative to the reagent blank. The calibration curve
was obtained by measuring standard gallic acid solutions, following the procedure described above.
The obtained calibration curve in range of 85–1360 µg/mL assay solution was y = 0.000831x − 0.0216;
R2 = 0.9984 (x: concentration of gallic acid in µg/mL; y: absorbance at 350 nm). The concentration of
o-diphenols in extracts was expressed as mg gallic acid equivalent (GAE)/kg of EVOO.
2.7. Total Flavonoids Analyses (TF)
TF concentration in the methanolic EVOO-PEs was determined according to the spectrophotometric
assay described by Kim [27]. Diluted EVOO-PE (1 mL) was added to a 10 mL volumetric flask together
with water (4 mL), 5% solution of sodium nitrite (0.3 mL), 10% solution of aluminium chloride (0.3 mL)
and incubated at room temperature for 5 min. Furthermore, in a flask with 1 M sodium hydroxide
(2 mL) water up to 10 mL was added and the mixture was thoroughly mixed. The absorbance of the
pink mixture was determined at 510 nm. A calibration curve was prepared with catechin in range
of 20–200 µg/mL assay solution (y = 0.003608x − 0.001203; R2 = 0.9980; x: concentration of catechin
in µg/mL; y: absorbance at 510 nm). The amount of TF was expressed as mg catechin equivalents
(CE)/kg of EVOO.
2.8. Scavenging Effect Assay
The capacity of EVOO-PEs samples to scavenge the DPPH free radical was determined by
the procedure described by Villaño et al. [28] with some modifications as follows. Aliquots of five
different dilutions of EVOO-PE (0.1 mL) in methanol were added to 2.9 mL 7.5 × 10−5 M methanolic
solution of DPPH radical. After shaking, the solution was in the dark for 30 min and its absorbance
was measured at 517 nm. The DPPH scavenging effect was calculated as a percentage of DPPH
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discolouration using the equation % scavenging effect = (ADPPH − Asample)/ADPPH × 100, where ADPPH
is the absorbance of DPPH solution and Asample is the absorbance of the DPPH solution with added
EVOO-PE. The EC50 value was obtained from the linear regression of plotting the % of scavenging
effect against the concentration of diluted EVOO-PE and expressed as the concentration of TP in
EVOO-PE expressed in µg gallic acid equivalent (GAE)/mL EVOO-PE, leading to 50% reduction of the
initial DPPH concentration.
2.9. Cell Culture and Biological Activity
Human cervical carcinoma (HeLa) cells were obtained from cell culture bank (GIBCO
BRL-Invitrogen, Carlsbad, CA, USA). Human colon cancer (SW48) cells were obtained from cell
culture bank (ATCC-LGC, Wesel, Germany). These cell lines were grown as a monolayer culture in
Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, St. Louis, MO, USA), supplemented
with 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO, USA) in a humidified atmosphere
of 5% CO2 at 37 ◦C and were sub-cultured every 3–4 days. Biological activity of EVOO-PEs was
determined by 3-[4-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay [29] modified
accordingly. In short, the cells were seeded into 96-well tissue culture plates. The next day, different
concentrations of compounds were added to each well in quadruplicate. Upon 72 h incubation at
37 ◦C, the medium was aspirated, and the MTT dye (Sigma-Aldrich, St. Louis, MO, USA) was added.
Three hours later, the formed formazan crystals were dissolved in DMSO, the plates were mechanically
agitated for 5 min and the optical density at 545 nm was determined on a microtiter plate reader
(Awareness Technology Inc., Palm City, FL, USA). The cell viability of non-treated cells and cell treated
with the highest concentration of DMSO used for the highest dose of phenol extract was similar,
meaning that DMSO did not influence cell viability in used experimental conditions.
2.10. Statistical Data Analysis
The SciPy.stats library of Python 2.7. a software (Python Software Foundation, Beaverton,
OR, USA) package was used for statistical analysis. Results are shown as the mean values ± standard
deviation (SD). Analysis of variance (ANOVA) tests was used for assessing significant differences
among treatments. Pearson’s correlation tests were performed at the level of significance of 5% (p < 0.05)
to obtain correlations between biological effect expressed as IC65 and polyphenol content and also
between phenolic compounds with each other. A principal component analysis (PCA) was carried out
on the biological activity data. The IC65 values (concentrations that induce 65% cell growth inhibition)
were determined using a linear regression curve fit.
3. Results
3.1. Characteristics of Phenolic Extracts
In this study, we selected samples of five different EVOOs from cultivars: Oblica, Buža, Bjelica
and Žižolera since we have expected they differ in phenolic profile. There were two samples of EVOOs
prepared from olive cultivar Oblica differing in olive fruits processing. EVOO (Oblica) was prepared
from the immediately processed fresh olive fruits, whereas EVOO (Oblica-Sea) was prepared from the
olive fruits kept in the seawater before the process. This EVOO (Oblica-Sea) had a specific taste and
different phenolic profile [20].
Phenolic compounds from EVOOs were extracted using an optimised ultrasound probe assisted
liquid-liquid extraction (US-LLE) method [21] and analysed using different methods. The results
obtained by high-performance liquid chromatography with a diode-array detector (HPLC-DAD)
analysis of EVOO-PEs under chromatographic conditions are chromatograms with peaks that
correspond to different phenolics (Figure 1Sa–e). These are biomedically important HTyr, Tyr, oleacein
and 10 other minor phenolic compounds: p-hydroxybenzoic acid, homovanillyl alcohol, vanillic acid,
vanillin, p-coumaric acid, benzoic acid, ferulic acid, pinoresinol, cinnamic acid and apigenin. Phenolic
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acids like 3,4-dihydroxybenzoic, o-coumaric and syringic acid were not detected (ND). Oleacein, the
most abundant phenol was tentatively identified by comparing its Rt in HPLC chromatograms with
data found in the literature [24]. There could be some deviation in oleacein concentration, taking
into account the formation of methoxy hemiacetals in methanol-water solution [30]. The values of
concentrations (mg/kg EVOO) of each phenolic compound identified by HPLC-DAD analysis in the
EVOO-PEs derived from different olive oil cultivars (Oblica-Sea/Oblica, Buža, Bjelica and Žižolera)
are shown in Table 1. Values of total phenol (TP) concentrations are also shown in Table 1, as well as
o-diphenols, total flavonoids (TF) of EVOO-PEs which were obtained by spectrophotometric methods.
Table 1. Phenolic composition and antioxidant activity of (EVOO-PEs) obtained from different cultivars.
EVOO-PE (Cultivar)
Oblica-Sea Oblica Buža Bjelica Žižolera
TP (mg GAE/kg EVOO ± SD) 319 ± 48 A 682 ± 8 B 270 ± 8 A 423 ± 38 A 391 ± 34 A
o-diphenols (mg GAE/kg EVOO ± SD) 136 ± 4 A 277 ± 40 B 114 ± 3 C 122 ± 11 A,C 128 ± 7 A,C
TF (mg CE/kg EVOO ± SD) 279 ± 53 A 606 ± 71 B 199 ± 3 A 230 ± 42 A 241 ± 6 A
EC50 158 191 190 208 198
Phenolic compounds (mg/kg EVOO ± SD)
HTyr 12.73 ± 0.12 A 21.23 ± 0.15 B 4.07 ± 0.17 C 4.85 ± 0.10 D 4.48 ± 0.14 C,D
3,4-dihydroxybenzoic acid ND ND ND ND ND
Tyr 7.69 ± 0.11 A 9.26 ± 0.08 B 4.57 ± 0.01 C 5.47 ± 0.42 C,D 5.14 ± 0.12 D
p-hydroxybenzoic acid 0.11 ± 0.10 A 0.08 ±0.02 B 0.15 ± 0.01 A 0.09 ± 0.02 A,B 0.12 A ± 0.01 A
Homovanillyl alcohol 0.26 ± 0.03 A 0.43 ± 0.01 B 0.27 ± 0.02 A 0.17 ± 0.01 C 0.18 ± 0.01 A,C
Vanillic acid 0.95 ± 0.01 A 0.77 ± 0.02 B 0.92 ± 0.01 A 0.50 ± 0.01 C 0.69 ± 0.01 B
Syringic acid ND ND ND ND ND
Vanillin 0.30 ± 0.01 A 0.54 ± 0.01 B 0.46 ± 0.01 C 0.29 ± 0.01 A 0.37D ± 0.02 D
p-coumaric acid 0.32 ± 0.03 A 0.48 ± 0.01 B 0.35 ± 0.01 C 0.40 ± 0.02 C 0.37 ± 0.01 C
Benzoic acid 0.28 ± 0.14 A 0.25 ± 0.14 A 0.53 ± 0.10 A 1.75 ± 0.19 B 0.90 ± 0.36 A,B
Ferulic acid 0.24 ± 0.04 A 0.28 ± 0.03 A 0.25 ± 0.01 A 0.67 ± 0.07 B 0.61 ± 0.04 B
Oleacein 59 ± 1 A 173 ± 6 B 72 ± 1 C 43 ± 1 D 39 ± 1 E
o-coumaric acid ND ND ND ND ND
Pinoresinol 3.07 ± 0.04 A 4.69 ± 0.01 B 12.57 ± 0.06 C 5.40 ± 0.33 B 7.10 ± 0.16 D
Cinnamic acid 0.93 ± 0.01 A 1.06 ± 0.02 B 0.36 ± 0.02 C 0.41 ± 0.02 C 0.51 ± 0.01 D
Apigenin 1.36 ± 0.01 A 0.99 ± 0.06 B 1.01 ± 0.02 B 0.87 ± 0.01 B 0.85 ± 0.01 B
EVOO-PE: extra virgin olive oil phenolic extract. TP: total phenols. GAE: gallic acid equivalent. SD: standard
deviation. TF: total flavonoids. CE: catechin equivalent. EC50: concentration of TP in µg GAE/mL PE ± SD leading
to a 50% reduction of the initial DPPH concentration. HTyr: hydroxytyrosol. Tyr: tyrosol. ND: not detected.
The means within each row labelled by different capital letters A–D are significantly different (ANOVA test, p ≤ 0.05).
3.2. Biological Effects of EVOO-PEs on Cells Survival of HeLa and SW48
Biological activity upon treatment with EVOO-PEs was evaluated by the MTT assay using in vitro
experimental models: HeLa and SW48 cancer cell lines. Cells were treated with a series of dilutions
that were made by diluting full strength (100%) EVOO-PE to concentrations of 0.02–0.25% (v/v) of
EVOO-PE in the medium. As shown in Figure 1, all EVOO-PEs significantly inhibited HeLa and SW48
cells in a dose-dependent manner. The sensitivity of HeLa and SW48 cancer cells to EVOO-PE was
expressed in terms of the concentration of extract % (v/v) required to decrease biological activity to 65%
(IC65 value, Table 2). The chosen value, IC65, best describes the metabolic activity (cellular viability) of
HeLa and SW48 cancer cells under the influence of all samples of EVOO-PEs. The obtained data show
that EVOO-PEs from Žižolera and Bjelica had the highest biological effect on HeLa (Figure 1A) and on
SW48 (Figure 1B) cell lines. The smallest effect is visible upon cell treatment with EVOO-PE isolated
from Oblica (Figure 1A,B). At this moment we cannot give an explanation, based on phenolic extract
content, why Žižolera and Bjelica show the best biological effect.
Antioxidants 2020, 9, 453 7 of 15
Table 2. Biological activity of EVOO-PEs in HeLa and SW48 cells obtained from different cultivars
expressed as IC65 (in % v/v of EVOO-PE ± SD).
EVOO-PE (Cultivar)
Oblica-Sea Oblica Buža Bjelica Žižolera
HeLa IC65
(% v/v of EVOO ± SD) 0.14 ± 0.02
A 0.17 ± 0.02 A 0.15 ± 0.02 A 0.06 ± 0.01 B 0.01 ± 0.01 C
SW48 IC65
(% v/v of EVOO ± SD) 0.19 ± 0.15
A 0.25 ± 0.03 A 0.33 ± 0.09 A 0.19 ± 0.01 A 0.13 ± 0.05 A
EVOO-PE: extra virgin olive oil phenolic extract. HeLa: human cervical cancer cells. SW48: human colon cancer
cells. IC65: the concentration % (v/v) of EVOO-PE required to decrease biological activity to 65%. SD: standard
deviation. The means within each row labelled by different capital letters A–D are significantly different (ANOVA
test, p ≤ 0.05).
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3.3. Biological Effects of EVOO-PEs in Combination with Anticancer Drugs on Cells Survival of
HeLa and SW48
Different side effects of chemotherapy are well documented by Fletcher et al. [31]. In order to
investigate the possible value of EVOO-PEs to the overall condition of a cancer patient, we decided
to explore first the combined treatment EVOO-PEs and three types of anticancer drugs: irinotecan,
5-FU and cDDP. All the drugs are used in protocols for regular treatment of cervical and colon cancer
patients. Since it is known that anticancer drugs cause different damages in cells triggering further
cell death [32,33] we were interested does the pre-treatment (treatment of cancer cells with EVOO-PE
overnight (ON) and then with a drug) and/or post-treatment (treatment of cancer cells first with a drug
and then 6 h after with EVOO-PE) differently affect cells’ biological activity. For this purpose, 0.13%
(v/v) of EVOO-PE Buža was used since this specific EVOO-PE showed medium biological effect among
all EVOO-PEs tested (Figure 1A,B). The obtained data show that there were no statistical differences
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in HeLa cell survival upon pre- or post-treatment with EVOO-PE (Buža) in combination with tested
drugs: irinotecan and 5-FU (Supplementary Materials, Figure S2a–c). However, the data obtained
for the combination of EVOO-PE Buža with cDDP (Supplementary Materials, Figure S2c) showed
increased viability of HeLa cells compared to cells treated only with cDDP. In order to explore this
effect more closely, we decided to test other EVOO-PEs also in combination with cDDP and its derivate
carboplatin (CBP).
For this purpose, the post-treatment with 0.06% (v/v) dilution of EVOO-PEs was used in
combination with cDDP. The biological effect of EVOO-PEs in HeLa (Figure 2A) and SW48 (Figure 2B)
cells was similar. The strongest effect was visible with Oblica-Sea, Buža and Žižolera. Moreover, the
similar data were obtained on HeLa cells also in combination of all EVOO-PEs with CBP (Figure 2C).
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3.4. Statistical Analysis
Pearson correlation coefficients (r) (with the significance of p < 0.05 and p < 0.01) between biological
activity expressed as IC65, antioxidant activity and polyphenol content, and also between phenolic
compounds with each other are given in Table 3 and Table S1 in Supplementary Materials. As expected,
the biological activity (IC65) of the EVOO-PEs on HeLa and SW48 were highly correlated to each
other. Biological activities of EVOO-PEs on HeLa and SW48 were differently correlated to the phenolic
compounds. In the case of HeLa IC65, there was a significant negative correlation with ferulic acid
and weaker positive correlations with HTyr, homovanilyl alcohol, vanillic acid, oleacein and total
phenolic alcohols and weaker negative correlation with benzoic acid. However, in the case of SW48
IC65 there was only a weak negative correlation with ferulic acid and weak positive correlations with
homovanillyl alcohol and vanillic acid.
Furtherly, significant positive correlations between phenolic compounds concentration as TP and
o-diphenols; Tyr and HTyr; oleacein and homovanillyl alcohol; cinnamic acid and Tyr; total phenolic
alcohols and HTyr, Tyr, cinnamic acid and significant negative correlation as apigenin and EC50; total
phenolic acid and vanillic acid were observed (Table S1 in Supplementary Materials).
A principal component analysis (PCA) was carried out on biological activity data, including
viability measurement of HeLa and SW48 cancer cells treated with anticancer drugs cDDP and CBP
alone and in combination with five different EVOO-PEs. PCA showed that the first two principal
components explained 97.2% of the total variance (Figure 3), the first one accounted for 86.3%, and
the second one for 10.9%. The biplot on PC1 and PC2 shows grouping of EVOO-PE samples with
Oblica-Sea, Buža and Žižolera occurring in one group, and Bjelica and Oblica in the other one, together
with drug applied alone.
Table 3. Pearson correlation among the concentrations of different phenolic compounds in EVOO-PEs
and their antioxidant and biological activity in HeLa and SW48 cells.
HeLa IC65 SW48 IC65
HeLa IC65 NaN 0.881 *
SW48 IC65 0.881 * NaN
TP 0.203 −0.067
o-diphenols 0.498 0.196
TF 0.494 0.176
EC50 −0.50 −0.247
HTyr 0.627 0.231
Tyr 0.558 0.12
p-hydroxybenzoic acid −0.026 0.332
Homovanillyl alcohol 0.799 0.578
Vanillic acid 0.641 0.593
Vanillin 0.538 0.56
p-coumaric acid 0.181 0.043
Benzoic acid −0.669 −0.483
Ferulic acid −0.896 * −0.782
Oleacein 0.688 0.474
Pinoresinol 0.037 0.488
Cinnamic acid 0.522 0.074
Apigenin 0.573 0.321
Total phenolic alcohol 0.617 0.213
Total phenolic acids and derivatives −0.562 −0.594
HeLa: human cervical cancer cells. SW48: human colon cancer cells. IC65: the concentration % (v/v) of EVOO-PE
required to decrease biological activity to 65%, TP: total phenols. TF: total flavonoids. EC50: concentration of TP
in µg GAE/mL PE ± SD leading to 50% reduction of the initial DPPH concentration. Total phenolic alcohol: the sum
of concentrations of HTyr, Tyr and homovanillyl alcohols. HTyr: hydroxytyrosol. Tyr: tyrosol. * p < 0.05.
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4. Discussion
The EVOO-PEs were characterised by the difference in the concentration of their main phenolic
components and concentration levels of TPs, o-diphenols and TFs (Table 1). The main variations
in phenolic profile were observed between EVOO Oblica (the island of Ugljan) and oils originating
from the Istrian Peninsula (Buža, Bjelica and Žižolera). The ifference between two samples of
EVOO derived from the same cultivar Oblica is in the procedure of obtaini g olive oil from its fruit.
The EVOO (Oblica-Sea) is obtained through a procedure when the olive fruit is kept in the seawater
and have a specific taste and different p enolic profile [20]. T e EVOO (Oblica) obtained through the
method of crushing olive fruits immediately after the harvest, and in comparison to other samples
of EVOOs contains the highest levels of phenolic compounds, especially HTyr (21.23 ± 0.15 mg/kg
EVOO), Tyr (9.26 ± 0.08 mg/kg EVOO) and leacein (173 ± 6 mg/kg EVOO). This oil also has the
highest concentration of TPs, o-diphenols a TFs but the value indicating antioxidative levels EC50 is
almost the same as in the EVOOs from the Istrian Peninsula (Buža, Bjelica and Žižolera) and higher
in co parison to the EVOO (Oblica-Sea) (Table 1). The EVOOs (Buža, Bjelica and Žižolera) contain
similar values of all major phenolic compounds, which are lower in comparison to the EVOO (Oblica)
and EVOO (Oblica-Sea). The o ly exception is the content of lignan pinoresinol which has the highest
co centration in the EVOO (Buža) in the amount of 12.57 ± 0.06 mg/kg of EVOO. In general, high
variation in phe olic content due to several factors including geographic region of olive growth, olive
tree cultivar, agricultural techniques applied to cultivate olives, live maturity and processing of the
olives to oil is expected [34]. By selecting oils with different phenolic profiles, we wanted to explore the
possible difference in biological activity on cancer cells. Moreover, we were interested if the use of the
EVOO-PE in combinatio with anticancer drugs, i stead of a single phenolic compound, resulted in
possible synergistic effects of the bserved drug and compound mixture that could be very beneficial in
cancer treatments or the use of olive oil during the cancer therapy should be scheduled more properly.
According to the literature, the biological effects of olive oil phenolic extract were investigated
in several types of cancer cells such as promyelocytic leukaemia cells (HL60) [7], human transitional
bladder cancer cell line T24 and 5637 [12], non-melanoma skin cancers [13] and colorectal cancer
cell lines [8,10,11]. In our research, the biological activity of different EVOO-PEs against HeLa cells
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(Figure 1A) was determined at concentrations of 0.02%, 0.03%, 0.06%, 0.13% and 0.25% (v/v) of
EVOO-PE. Biological activity of EVOO-PEs on HeLa cells is in general proportional to concentration.
Furthermore, the biological activity of particular EVOO-PEs observed at each concentration level
specifically was different with the exception of Oblica-Sea and Buža, with Oblica showing weakest,
while Bjelica and Žižolera the greatest effect. At 0.13% and 0.25% (v/v) of EVOO-PE, the difference
among cultivars is less pronounced; Buža and Žižolera show a slightly higher effect on cell viability
than Oblica-Sea, Oblica and Buža. In the case of SW48 cells, EVOO-PE Oblica-Sea, Buža and Žižolera
have a similar effect, higher than Oblica and Bjelica at each concentration level (Figure 1B). No statistical
difference was observed in the % of cell survival rate at different concentration levels of EVOO-PEs
from Oblica-Sea, Buža and Žižolera cultivars with the exception of Žižolera at 0.25% (v/v) of EVOO-PE.
The largest variation in the biological activity of different EVOO-PEs at the same concentration levels
was observed at 0.02% (v/v). The Pearson correlation test reveals different relationship among IC65
values and phenolic compound content of different EVOO-PEs in the case of HeLa and SW48 cells.
However, in order to understand which components of EVOO-PEs are responsible for the observed
effect requires further investigation.
In the second part of our study, we were interested in exploring the biological effect of EVOO-PEs
in combination with broadly used anticancer drugs. Chemotherapy, despite its many side effects,
is still the most popular way of treating cancer and sometimes the only way. Polyphenolic compounds
give hope for an improvement of chemotherapy efficacy as well as the reduction of side effects.
For instance, platinum drugs are widely used in the treatment of different types of cancer; however, its
application is limited because of development of drug resistance and many undesirable side effects
in humans [35,36]. Nevertheless, some reports have shown that platinum drugs-induced reactive
oxygen species (ROS) formation in vivo and in vitro, which is responsible for the severe side effects of
cDDP therapy, including nephrotoxicity and hepatotoxicity which can be reduced by the addition of
antioxidants [37]. To the best of our knowledge, there has been only one study researching the biological
effect of olive oil phenolic extract in combination with different anticancer drugs. Coccia et al. [19]
have investigated the biological activity of EVOO-PE with drugs paclitaxel and mitomycin C in vitro
in T24 and 5637 bladder cancer cells. The authors showed that simultaneous treatment of mitomycin C
and EVOO-PE reduced the drug cytotoxicity due to inhibition of ROS production. The co-treatment
of T24 cells with paclitaxel and the polyphenol extract strongly increased the apoptotic cell death
compared to paclitaxel alone. The authors suggested that olive oil consumption exerts health benefits
and may represent a starting point for the development of new anticancer strategies. In our preliminary
research, the combination of anticancer drugs (irinotecan, 5-FU, cDDP) and one of the EVOO-PEs,
Buža showed no significant differences in biological effect on HeLa cell line if the cells were treated
with EVOO-PE, before or after the drug was added (before DNA/after DNA damage; Supplementary
Materials Figure S2). However, only the combination of EVOO-PE Buža with cDDP resulted in
increased viability of HeLa cells. Following these results, cDDP was selected for further viability
studies where a combination of cDDP with five different EVOO-PEs, from cultivars Bjelica, Buža,
Žižolera, Oblica added 6 h after cDDP, was investigated.
Statistical analysis (PCA) was performed on biological activity data (Figure 2A–C) to analyse
whether the different phenolic profiles of EVOOs (see Table 1) exert a different effect on cells survival
when applied with broadly used anticancer drugs cDDP and CBP. The effect of the combination of
EVOO-PE in post-treatment and drugs were examined in three different cases: the effect of EVOO-PEs
with cDDP on HeLa and SW48 cells and the effect of EVOO-PEs with CBP on Hela cells. The biplot on
PC1 and PC2 (Figure 3) shows that EVOO-PEs Oblica and Bjelica are in the same group with drug
applied alone, while the EVOO-PEs Oblica-Sea, Buža and Žižolera form another group, in the each of
three examined cases, leading to the conclusion that EVOO-PEs Oblica-Sea, Buža and Žižolera boosted
the metabolic activity of cancer cells after the treatment with platinum drugs, while Oblica and Bjelica
do not. There could be several reasons for this. It is known that among DNA damages cDDP and CBP
can induce the formation of ROS [37–39]. It is known that phenolic compounds act as antioxidants
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and lower the effects of ROS [40]. All analysed EVOO-PEs show similar antioxidative capacity,
expressed as EC50 with the exception of EVOO-PE Oblica-Sea with slightly higher capacity (Table 1).
However, EVOO-PE Oblica-Sea, Buža and Žižolera show a significantly higher chemoprotective effect
on cancer cells indicating there is probably some additional mechanism besides antioxidant, what
could be related with a specific phenolic profile of these EVOOs. There is a possibility that EVOO-PEs
interact with some proteins involved in DNA damage response by increasing their functionality.
Furthermore, it is interesting to notice that EVOO Oblica-Sea obtained from olives kept in seawater
before processing differs from EVOO Oblica with specific taste but also regarding different biological
potential. Since EVOO (Oblica-Sea) shows a greater chemoprotective effect, it would be interesting to
further investigate this issue [20]. In addition, it is important to emphasise that due to the observed
EVOO-PEs chemoprotective effect on cancer cells it will be interesting to explore which phenolic
compounds from olive oil could have a protective effect in the regeneration process of normal cells
damaged during chemotherapy for the possible use of specific olive oil components as compounds to
induce a decrease in chemotherapy side effects.
5. Conclusions
In this study, we have described phenolic profiles of several EVOOs from different cultivars
(Oblica, Bjelica, Buža, Žižolera) of two geographic origins (island of Ugljan and Istrian Peninsula,
Croatia) and investigated biological effect of EVOO-PEs on human cervical (HeLa) and human colon
(SW48) cancer cell lines alone and in combination with different anticancer drugs. All EVOO-PEs have
a similar biological effect on HeLa and SW48 cells but in combination with broadly used anticancer
drugs the EVOO-PEs Oblica-Sea, Buža and Žižolera show the highest chemoprotective effect. These
findings demonstrate the necessity of careful consummation of olive oil during chemotherapy for
cancer patients. Further investigation is needed to explore the molecular mechanism of this protection
and possible use of specific phenols individually for reduction of side effects of chemotherapy.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3921/9/5/453/s1,
Figure S1: HPLC chromatogram of EVOO-PEs at 278 nm. Oblica-Sea (A); Oblica (B); Buža (C); Bjelica (D); Žižolera
(E). HTyr: hydroxytyrosol, Tyr: tyrosol. Figure S2: HeLa cells viability after 72 h exposure to various doses of
anticancer drugs and pre-treatment overnight (ON) or post-treatment (6 h after anticancer drugs) with 0.13% (v/v)
of EVOO-PE (Buža). Irinotecan and 0.13% (v/v) of EVOO-PE (Buža) (A). 5-fluorouracil (5-FU) and 0.13% (v/v) of
EVOO-PE (Buža) (B). Cisplatin (cDDP) and 0.13% (v/v) of EVOO-PE (Buža) (C). Values are the mean ± SD, n = 4.
Means by different letters are significantly different (ANOVA test, p ≤ 0.05), Table S1: Pearson correlation among
the concentrations of different phenolic compounds in EVOO-PEs and their antioxidant and biological activity in
HeLa and SW48 cells.
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38. Brozović, A.; Majhen, D.; Roje, V.; Mikac, N.; Jakopec, S.; Fritz, G.; Osmak, M.; Ambriović-Ristov, A. αvβ3
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